Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.
The ADDF will be featured in an upcoming episode of Innovations with Ed Begley Jr., airing via Discovery Channel later this year.
Melvin R. Goodes Prize supports innovative projects by top researchers while honoring pioneering legacy of former Warner-Lambert CEO.
Carmel Valley's newest winery, Jarman Wines, will introduce two premium varietals to benefit the Alzheimer's Drug Discovery Foundation (ADDF) and to honor the matriarch of the family whose name graces the wines created for her.
Cleveland Clinic Lou Ruvo Center for Brain Health is now recruiting participants for a new, multicenter Alzheimer’s disease (AD) treatment trial, Rasagiline Rescue (R2), which is designed to determine if treatment with rasagiline is associated with improved brain glucose metabolism and improvement in memory.
A mother's voice is the first thing we hear from the time we exit the womb. And its the voice we continue to hear throughout our lives. We model our mother's voice when we first learn to talk. The same voice guides us as we begin to walk. It warns you of potential harm and radiates warmth when you need consolation.
On Monday, April 27, 2015, American theatre director, choreographer, film director, and performer Susan Stroman hosted the ADDF's Ninth Annual Connoisseur’s Dinner. More than $2.8 million was raised to support Alzheimer's drug discovery and development.
On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the ADDF's Fifth Annual Great Ladies Luncheon & Fashion Show in Washington, DC. Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer's.
Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the ADDF awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.
The ADDF announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109.